Complete prevalence and indicators of cancer cure: enhanced methods and validation in Italian population-based cancer registries.
Italy
cancer cure indicators
cure fraction
cure prevalence
prevalence
survival
time to cure
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
17
02
2023
accepted:
09
05
2023
medline:
22
6
2023
pubmed:
22
6
2023
entrez:
22
6
2023
Statut:
epublish
Résumé
To describe the procedures to derive complete prevalence and several indicators of cancer cure from population-based cancer registries. Cancer registry data (47% of the Italian population) were used to calculate limited duration prevalence for 62 cancer types by sex and registry. The incidence and survival models, needed to calculate the completeness index ( For the most frequent cancer types, the Weibull survival model stratified by sex and age showed a very good fit with observed survival. For men diagnosed with any cancer type at age 65-74 years, CF was 41%, while the NS was 49% until age 100 and 50% until age 90. In women, similar differences emerged for patients with any cancer type or with breast cancer. Among patients alive in 2018 with colorectal cancer at age 55-64 years, 48% were already cured (had reached their specific TTC), while the cure prevalence (lifelong probability to be cured from cancer) was 89%. Cure prevalence became 97.5% (2.5% will die because of their neoplasm) for patients alive >5 years after diagnosis. This study represents an addition to the current knowledge on the topic providing a detailed description of available indicators of prevalence and cancer cure, highlighting the links among them, and illustrating their interpretation. Indicators may be relevant for patients and clinical practice; they are unambiguously defined, measurable, and reproducible in different countries where population-based cancer registries are active.
Identifiants
pubmed: 37346072
doi: 10.3389/fonc.2023.1168325
pmc: PMC10280813
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1168325Investigateurs
Fabiola Giudici
(F)
Ellina Evdokimova
(E)
Elena Demuru
(E)
Gemma Gatta
(G)
Paolo Contiero
(P)
Giovanna Tagliabue
(G)
Riccardo Capocaccia
(R)
Massimo Rugge
(M)
Teresa Intrieri
(T)
Martina Taborelli
(M)
Lucia Bisceglia
(L)
Stefano Rosso
(S)
Claudia Casella
(C)
Antonietta Torrisi
(A)
Giovanni Maifredi
(G)
Monica Lanzoni
(M)
Alessio Gili
(A)
Sergio Mazzola
(S)
Maria Francesca Vitale
(MF)
Erica Giacomazzi
(E)
Silvia Ghisleni
(S)
Maria Adalgisa Gentilini
(MA)
Fabio Vitadello
(F)
Concetta Patrizia Rollo
(CP)
Stefano Marguati
(S)
Luciana Del Riccio
(LD)
Maria Rotella
(M)
Alessandra Sessa
(A)
Antonino Colanino Ziino
(AC)
Ivan Cometti
(I)
Roberta Bosu
(R)
Informations de copyright
Copyright © 2023 Toffolutti, Guzzinati, De Paoli, Francisci, De Angelis, Crocetti, Botta, Rossi, Mallone, Zorzi, Manneschi, Bidoli, Ravaioli, Cuccaro, Migliore, Puppo, Ferrante, Gasparotti, Gambino, Carrozzi, Stracci, Michiara, Cavallo, Mazzucco, Fusco, Ballotari, Sampietro, Ferretti, Mangone, Rizzello, Mian, Cascone, Boschetti, Galasso, Piras, Pesce, Bella, Seghini, Fanetti, Pinna, Serraino, Dal Maso and AIRTUM Working Group.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BMC Med Res Methodol. 2011 Jun 22;11:96
pubmed: 21696598
Ann Oncol. 2004 Jul;15(7):1136-42
pubmed: 15205210
Int J Cancer. 2022 Feb 1;150(3):406-419
pubmed: 34551126
Cancer Manag Res. 2022 Oct 31;14:3105-3118
pubmed: 36340999
J Natl Cancer Inst Monogr. 2014 Nov;2014(49):145-86
pubmed: 25417231
Biometrics. 2012 Mar;68(1):113-20
pubmed: 21689081
Front Oncol. 2023 Apr 24;13:1114701
pubmed: 37168378
J Clin Oncol. 2010 May 20;28(15):2520-8
pubmed: 20406936
Int J Epidemiol. 2000 Apr;29(2):197-207
pubmed: 10817114
Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):561-70
pubmed: 23535024
Eur J Cancer. 2009 Apr;45(6):1067-79
pubmed: 19131242
Epidemiol Prev. 2017 Mar-Apr;41(2 Suppl 1):1-244
pubmed: 28629213
BMC Med Res Methodol. 2020 Mar 26;20(1):71
pubmed: 32216765
Cancer Epidemiol. 2013 Dec;37(6):836-42
pubmed: 24042025
Br J Cancer. 2012 Sep 25;107(7):1195-202
pubmed: 22892390
Tumori. 2019 Jun;105(3):199-204
pubmed: 30905274
Int J Cancer. 2023 Feb 15;152(4):738-748
pubmed: 36104936
Lancet Oncol. 2022 Dec;23(12):1525-1536
pubmed: 36400102
Cancer Epidemiol. 2012 Apr;36(2):148-52
pubmed: 22000329
Cancer Epidemiol Biomarkers Prev. 2020 Mar;29(3):625-635
pubmed: 31932416
Stat Med. 1997 Feb 28;16(4):425-40
pubmed: 9044530
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
Biostatistics. 2007 Jul;8(3):576-94
pubmed: 17021277
Cancer Epidemiol. 2018 Apr;53:72-80
pubmed: 29414635
Cancer. 2022 Oct;128(20):3663-3673
pubmed: 35972380
Lancet Oncol. 2014 Jan;15(1):23-34
pubmed: 24314615
Cancer Epidemiol. 2019 Jun;60:93-101
pubmed: 30933890
BMC Cancer. 2012 Oct 08;12:460
pubmed: 23043308
Int J Epidemiol. 2020 Oct 1;49(5):1517-1525
pubmed: 32984907
Eur J Cancer. 2018 Oct;102:69-81
pubmed: 30138773
Ann Oncol. 2014 Nov;25(11):2251-2260
pubmed: 25149707
Lancet Oncol. 2016 Oct;17(10):1354-1356
pubmed: 27733259
Epidemiol Prev. 2010 Sep-Dec;34(5-6 Suppl 2):1-188
pubmed: 21220827
J Registry Manag. 2010 Fall;37(3):86-103
pubmed: 21462880
J Clin Oncol. 2017 Oct 20;35(30):3516-3517
pubmed: 28834437
Cancer Med. 2020 Aug;9(15):5632-5642
pubmed: 32436657
JAMA Oncol. 2018 Nov 1;4(11):1519-1526
pubmed: 29860375
Cancer Med. 2019 Aug;8(9):4497-4507
pubmed: 31207165
Epidemiol Prev. 2014 Nov-Dec;38(6 Suppl 1):1-122
pubmed: 25759295
Am J Hosp Palliat Care. 2015 Aug;32(5):477-83
pubmed: 24558172
Br J Cancer. 2008 Jul 8;99(1):219-23
pubmed: 18594545
J Natl Cancer Inst Monogr. 2014 Nov;2014(49):244-54
pubmed: 25417238
Stat Med. 1999 Feb 28;18(4):441-54
pubmed: 10070685
BMC Cancer. 2018 Feb 9;18(1):169
pubmed: 29426306